Canada Markets close in 1 hr 37 mins

Curative Biotechnology, Inc. (CUBT)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0147+0.0000 (+0.14%)
As of 11:34AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.0147
Open0.0135
BidN/A x N/A
AskN/A x N/A
Day's Range0.0135 - 0.0151
52 Week Range0.0051 - 0.0310
Volume50,720
Avg. Volume353,217
Market Cap15.674M
Beta (5Y Monthly)230.42
PE Ratio (TTM)N/A
EPS (TTM)-0.0100
Earnings DateDec 11, 2023 - Dec 16, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Curative Biotechnology, Inc. Announces Nomination of Dr. Jeffrey Liebmann to Board of Directors

    Appointment of Independent Director to become effective upon approval by and listing of common stock on a National Exchange Boca Raton, FL, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases today announced its nomination to its Board of Directors of Dr. Jeffrey Liebmann. Dr. Liebmann is expected to join its Board of Directors as an indepe

  • GlobeNewswire

    Curative Biotechnology Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset Acquisitions

    Appoints Paul Michaels Co-CEO of Parent and CEO of Subsidiary Boca Raton, FL, June 06, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel therapies for rare diseases and conditions, today announced that the registration process has begun for the creation of a subsidiary in Japan with an official incorporation date expected August 1, 2023, to facilitate licensing transactions and asset lic

  • GlobeNewswire

    Curative Biotechnology, Inc. Files Patent on Ophthalmic Formulation

    Topical Administration Capable of Delivering Metformin to Choroid, RPE, and Retina Boca Raton, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel therapies for rare diseases and conditions, announced today that a Patent Cooperation Treaty (PCT) application was duly filed in the U.S. Receiving Office on May 22, 2023, claiming priority to U.S. Provisional Application No. 63/345,